

EQA round: TDM1/24 - Therapeutic Drugs

Setup: groups - M (measurement principle); Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	CVP = consensus of all participants	UL = upper limit
N _{tot} = total number of the results	U _{AV} = expanded uncertainty of the assigned value (k = 2)	N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					Traceability													
							AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel} [%]	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel} [%]			
Set 1																									
(81) Digoxin	[µg/L]				14																				
Sample A1		1,31	0,23	17	14																				
(4) LIA, ILMA		1,26	0,43	34	7	0								CRV	1,3	0,033	36%	0,832	1,77	14	12	86			
Other					7	0																			
Sample B1		0,685	0,14	20	14									CRV	0,694	0,017	36%	0,444	0,944	14	12	86			
(4) LIA, ILMA		0,694	0,28	40	7	0																			
Other					7	0																			
(84) Phenobarbital	[mg/L]				6																				
Sample A1																									
Other					6	0																			
Sample B1																									
Other					6	0																			
(85) Phenytoin	[mg/L]				1																				
Sample A1																									
Other					1	0																			
Sample B1																									
Other					1	0																			
(86) Carbamazepin	[mg/L]				9																				
Sample A1		4,49	0,42	9,4	9		CVP	4,25	0,14	20%	3,4	5,1													
(2) EIA (EMIT, CEDIA)		4,69	0,53	11	5	0																			
Other					4	0																			
Sample B1		6	0,89	15	9		CVP	6,09	0,16	20%	4,87	7,31													
(2) EIA (EMIT, CEDIA)		6,33	0,42	6,6	5	0																			
Other					4	0																			
(88) Valproic acid	[mg/L]				12																				
Sample A1		79,3	5,8	7,3	12		CVP	78,2	1,3	20%	62,5	93,9													
(2) EIA (EMIT, CEDIA)		84,3	3,3	4	5	0																			
Other					7	0																			
Sample B1		125	8,6	6,9	12		CVP	123	2	20%	98,4	148													
(2) EIA (EMIT, CEDIA)		130	2,1	1,6	5	0																			

EQA round: TDM1/24 - Therapeutic Drugs

Deadline: 26.4.2024

Setup: groups - M (measurement principle); Slovakia; minimal size of the groups n = 5

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					Traceability								
							AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel} [%]	AV	U _{AV}	D _{max}	LL	UL	N _{eva}
Other					4	0	1x 1, 3x 6													
Sample B2		21,7	2	9	14		CVP	21,5	0,57	28%	15,4	27,6	14	14	100					
(2) EIA (EMIT, CEDIA)		20,9	2,6	12	5	0						5								
(4) LIA, ILMA		22,6	0,9	4	5	0						5								
Other					4	0						4								
							1x 1, 3x 6													